Know Cancer

forgot password

Reacquisition of RAI Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244: A Pilot Study

18 Years
Not Enrolling
Thyroid Cancer

Thank you

Trial Information

Reacquisition of RAI Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244: A Pilot Study

Inclusion Criteria:

- Patients > or = to 18 years-old

- Patients must have histopathologically confirmed at MSKCC differentiated thyroid
carcinoma of follicular cell origin (D-TC-FCO), which includes papillary, follicular,
or Hürthle cell histology, along with their respective variants.

- Pathology specimen from the original tumor (thyroid) and/or metastases must be
available for genotyping.

- RAI-refractory metastatic disease on structural imaging, defined as any one of the
following (as described in MSKCC protocol 08-066):

- index metastatic lesion non-RAI avid on a diagnostic RAI scan performed up to 2
years prior to enrolment in the current study, OR

- RAI-avid metastatic lesion which remained stable in size or progressed despite
RAI treatment 6 months or more prior to entry in the study. Lesions will be
assessed by 2 independent observers in nuclear medicine and in endocrinology.
There is no minimal size limit for the index lesion.

- Patients with FDG avid lesions

- Evaluable disease by RECIST

- Preliminary reproductive toxicology data indicate that AZD6244 can have adverse
effects on embryofetal development and survival at dose levels that do not induce
maternal toxicity in mice. For this reason, female patients will need to be
post-menopausal or with negative serum pregnancy test if pre-menopausal. Patients of
childbearing potential must agree to employ adequate contraception throughout the

- ANC > 1500 per mm3, platelets > 100,000 per mm3, and hemoglobin > 9 g/dL

- ALT/SGOT and AST/SGPT ≤ 2.5 X upper limit of normal (ULN)

- Bilirubin ≤ 1.5 X ULN

- Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

- Patients may not be receiving any other investigational agents.

- Patient with chronic renal insufficiency, as defined initially by an estimated
creatinine clearance of < 30 ml/minute calculated using the Cockcroft and Gault
equation: (140 - age in years) X (weight in kg) X (0.85 if female)/72 X serum Cr. If
estimated creatinine clearance is < 30 ml/min, a 24 hour urine creatinine clearance
may be collected and a patient would be eligible if the creatinine clearance is >30

- Patients unable to follow a low iodine diet, patients requiring medication with high
content in iodide (amiodarone), or patients receiving IV iodine containing contrast
as part of radiographic procedure.

- Patients with clinically significant cardiovascular disease as defined by the

- LVEF < institutional LLN

- New York Heart Association grade III or greater congestive heart failure

- uncontrolled hypertension, defined as systolic blood pressure > 180 mmHg OR
diastolic blood pressure > 105 mmHg, on at least 2 repeated determinations on
separate days within past 3 months

- Uncontrolled coronary artery disease, angina, congestive heart failure, or
ventricular arrhythmia requiring acute medical management.

- Patient with known hypersensitivity to Thyrogen (human recombinant thyrotropin).

- Patients with a history of allergic reactions attributed to compounds of similar
chemical or biologic composition to agents used in the study.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection or psychiatric illness/social situations that would limit compliance with
study requirements.

- Pregnant women will be ineligible; breast feeding should be discontinued if the
mother is treated with AZD6244.

- Brain metastases or spinal cord compression unless treated and stable (for at least 3
months) off steroids.

- Mean QTc interval >450 ms

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Determine whether RAI uptake in thyroid cancer mets increases after 4 weeks tx with the selective MEK inhibitor AZD6244 in patients with RAI-refractory thyroid cancer.

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Alan Ho, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

September 2009

Completion Date:

April 2013

Related Keywords:

  • Thyroid Cancer
  • thyroid
  • metastases
  • AZD6244
  • 09-048
  • Thyroid Neoplasms
  • Thyroid Diseases



Memorial Sloan-Kettering Cancer CenterNew York, New York  10021